Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin IV plus intravesical gemcitabine in high-risk NMIBC
CTR20230905Phase 2Active
- Sponsor
- RemeGen
- Start
- Jun 2023
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, gemcitabine in non-muscle-invasive bladder cancer (NMIBC), transitional cell carcinoma (TCC), sponsored by RemeGen. Started Jun 2023; status: active.
02
Drugs
disitamab vedotingemcitabine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20230905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230905.